Phase I trial of docetaxel and short infusion Gemcitabine given every two weeks for advanced solid tumors

被引：0
|
作者：
Davis, TH
Rigas, JR
Maurer, LH
Pipas, JM
Obrocea, M
Tretter, CP
Smith, EL
Meyer, L
Hammond, S
机构：
[1] Norris Cotton Canc Ctr, Lebanon, NH USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
642P
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [1] Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
    Sanborn, Sharon L.
    Gibbons, Joseph
    Krishnamurthi, Smitha
    Brell, Joanna M.
    Dowlati, Afshin
    Bokar, Joseph A.
    Nock, Charles
    Horvath, Nancy
    Bako, Jacob
    Remick, Scot C.
    Cooney, Matthew M.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 453 - 460
  • [2] Phase I trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors
    Sanborn, S. L.
    Cooney, M.
    Gibbons, J.
    Brell, J.
    Savvides, P.
    Krishnamurthi, S.
    Bokar, J.
    Horvath, N.
    Ness, A.
    Remick, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
    Sharon L. Sanborn
    Joseph Gibbons
    Smitha Krishnamurthi
    Joanna M. Brell
    Afshin Dowlati
    Joseph A. Bokar
    Charles Nock
    Nancy Horvath
    Jacob Bako
    Scot C. Remick
    Matthew M. Cooney
    Investigational New Drugs, 2009, 27 : 453 - 460
  • [4] Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
    Rothenberg, ML
    Sharma, A
    Weiss, GR
    Villalona-Calero, MA
    Eckardt, JR
    Aylesworth, C
    Kraynak, MA
    Rinaldi, DA
    Rodriguez, GI
    Burris, HA
    Eckhardt, SG
    Stephens, CD
    Forral, K
    Nicol, SJ
    Von Hoff', DD
    ANNALS OF ONCOLOGY, 1998, 9 (07) : 733 - 738
  • [5] A phase I trial of SR271425 given as a one hour infusion every 3 weeks to patients with advanced solid tumors.
    Wadler, S
    Loh, E
    Pilat, MJ
    Malburg, L
    Holloway, S
    Matthews, N
    Shackleton, G
    Valdivieso, M
    Lorusso, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 142S - 142S
  • [6] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [7] A phase I study of gemcitabine and docetaxel for advanced stage solid tumors
    Poole, ME
    Bernard, SA
    Churchel, MA
    Weissler, MC
    Calvo, B
    Cance, W
    Ollila, D
    Koruda, M
    Behrns, K
    Detterbeck, FC
    CANCER INVESTIGATION, 2003, 21 (03) : 350 - 354
  • [8] Phase I study on docetaxel and Gemcitabine in patients with advanced solid tumors
    Jaremtchuk, AV
    Zarba, JJ
    Ferro, A
    ANNALS OF ONCOLOGY, 1998, 9 : 138 - 139
  • [9] A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors
    Kakolyris, S
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Agelaki, S
    Kalbakis, K
    Androulakis, N
    Vardakis, N
    Vamvakas, L
    Georgoulias, V
    ONCOLOGY, 2001, 61 (04) : 265 - 270
  • [10] Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors
    Planting, AST
    Schellens, JHM
    van der Burg, MEL
    de Boer-Dennert, M
    Winograd, B
    Stoter, G
    Verweij, J
    ANTI-CANCER DRUGS, 1999, 10 (09) : 821 - 827
12345